June 3, 2019

Intraoperative Enteroscopy in Peutz–Jeghers Syndrome

Case Report and Images of Note

By Carole Burke, MD


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy


Peutz-Jeghers Syndrome (PJS) is a hereditary cancer syndrome characterized by benign hamartomatous, primarily gastrointestinal (GI), polyps; muco-cutaneous pigmentation; and a high predisposition to many intestinal and extra-intestinal cancers.

PJS is caused by a mutation of the STK11/LKB1 gene, which normally functions as a tumor suppressor and cell growth regulator. Mutation disrupts the gene’s ability to curtail cell division, leading to polyps and cancer.

Approximately half of cases are inherited from a parent; the remainder occur in patients with no family history of PJS and appear to result from a spontaneous mutation. A patient with PJS has a 50% chance of passing the condition on to their offspring. PJS is relatively rare, affecting one in 25,000 to 300,000 live births of all ethnicities.

Polyps typically occur beginning in childhood in the small intestine but also manifest throughout the intestinal tract and outside the intestinal tract in the renal pelvis, lungs, gall bladder, nasal passages, urinary bladder and ureters. Hyperpigmentation — dark blue or brown macules — on the border of the lips and inside the mouth are a tip-off to the diagnosis of PJS and appear in childhood. The pigment may lessen in adolescence and adulthood, and can also occur near the eyes and nostrils, in the perianal area and sometimes on the hands and feet.

PJS patients have a 90% lifetime risk of cancer, including colorectal (most common — lifetime risk 39 percent), gastric, pancreatic, lung, breast, uterine, cervical, testicular and ovarian.

Small bowel obstruction resulting from polyps is a common complication, often in childhood, requiring surgical intervention. Regular imaging studies (MRI/MRE or CT/CTE) and endoscopic surveillance and polypectomy of the intestinal tract, beginning in early adolescence, can reduce the likelihood of intestinal complications. Many other organs in PJS patients require special surveillance for potential malignancies.

Case Report

A 39-year-old Asian female presented to Cleveland Clinic’s Digestive Disease & Surgery Institute for evaluation of recurrent small bowel obstruction (SBO) in the preceding year. She recently had been diagnosed with PJS, with genetic testing showing deletion of exons 2–8 in the STK11 gene.

She had undergone abdominal surgery of unknown type at age 2 years.


Endoscopic evaluation during the previous six months revealed multiple hamartomatous polyps, 0.5–4 cm in size, throughout the stomach, small bowel and colon. Computerized tomographic enterography revealed multiple dilated small bowel loops with scattered foci of intussusception, suspected to be due to hamartomatous polyps, leading to recurrent SBO.

Exploratory laparotomy with surgically assisted enteroscopy to the terminal ileum and removal of clinically significant polyps, i.e., “clean sweep,” was planned.

Intraoperative findings included extensive intra-abdominal adhesions and prior small bowel resection, with an anastomotic stricture 60 cm proximal to the ileocecal valve. Surgical adhesiolysis and small bowel resection was performed, along with endoscopic removal of more than 30 polyps >10 cm in size and more than 35 polyps 2–10 cm in size.

These unique intraoperative endoscopic images, obtained with the patient’s consent and originally published in the American Journal of Gastroenterology, depict:

Figure 1a — The transilluminated jejunum and ileum.

Figure 1b — Large polyps in the jejunum and ileum.

Figure 1c — Resection of polyps using hot snares and retrieval with a Roth Net or by enterotomy.


The patient has done well after surgery and returns for routine procedures recommended for patients with PJS.


We are fortunate that innovations in small bowel imaging such as video capsule endoscopy and MRI enterography are available to screen for small bowel polyps, and that advances in endoscopic equipment such as balloon enteroscopy are available to remove polyps deep in the small intestine, avoiding the need for emergency surgery in PJS patients.

Dr. Burke is Vice Chair of Cleveland Clinic’s Department of Gastroenterology and Hepatology and Section Head of Polyposis in the Sanford R. Weiss, MD, Center for Hereditary Colorectal Neoplasia.

Adapted from Rao BB, Kalady MF, Burke CA. Intraoperative Enteroscopy in Peutz-Jeghers Syndrome. Am J Gastroenterol. 2018 Jun;113(6):799.

Intraoperative images © The American College of Gastroenterology 2018. Used with permission.

Related Articles

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

February 7, 2024
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

February 5, 2024
Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

January 30, 2024
Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival